PeptiDream, Inc. engages in the biopharmaceutical business that includes research and development of non-standard peptide therapeutics. The company is headquartered in Kawasaki-Shi, Kanagawa-Ken and currently employs 621 full-time employees. The company went IPO on 2013-06-11. The firm operates the Peptide Discovery Platform System (PDPS), a drug development platform system and conducts research and development (R&D) on new drug candidates based on the joint R&D with pharmaceutical companies in Japan and overseas. The firm is involved in the business centered on drug development based on special peptides. The firm's businesses include drug discovery joint R&D, PDPS technology loan (PDPS technology license) and expansion of its own pipeline through strategic alliance (strategic alliance or in-house drug discovery).
Follow-Up Questions
PeptiDream Inc のCEOは誰ですか?
Dr. Patrick Reid は PeptiDream Inc の President で、2008 から在籍しています。